Cantor Fitzgerald Reiterates Overweight on Sanara MedTech, Maintains $49 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating on Sanara MedTech (NASDAQ:SMTI), with a maintained price target of $49.
February 06, 2024 | 2:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald reaffirms an Overweight rating on Sanara MedTech, with a price target of $49.
The reiteration of an Overweight rating by a reputable analyst firm like Cantor Fitzgerald, along with a maintained price target, is a positive signal for investors. It suggests confidence in the company's future performance and potential for stock price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100